Home > News > Headline News > Archive

Click on title to read the full article.

Research and Markets: Breast Cancer Drug Pipeline Update 2012 - Currently There Are 331 Companies plus Partners Developing 450 D

February 29, 2012

By Sun Herald

Delcath Announces First CHEMOSAT Procedures in Germany

February 29, 2012

By Johann Wolfgang Goethe University Hospital

Delcath announced today that the first patients in Germany have been treated with the Delcath Hepatic CHEMOSAT® Delivery System at the Johann Wolfgang Goethe University Hospital, a premier European cancer treatment and research center located in Frankfurt.

PET clarifies difficult breast cancer cases

February 26, 2012

By Dekcia Honen Yard

Positron emission tomography (PET) can help clinicians pinpoint a diagnosis in breast cancer patients with formerly inconclusive assessments and can predict prognosis in an aggressive form of the disease, two recent studies show

COUNTERFEIT DRUG LABELED AS AVASTIN® (BEVACIZUMAB) IN THE UNITED STATES

February 16, 2012

By Genentech

Roche and Genentech have been informed that a counterfeit product, labeled as Avastin (bevacizumab), has been distributed in the United States. The counterfeit product is not safe or effective and should not be used. Chemical analyses of the counterfeit vials tested to date have confirmed the product does not contain the active ingredients for Avastin.

Need to Biopsy at Metastatic Breast Cancer Relapse?

February 13, 2012

By Nick Mulcahy

Taking a biopsy of metastatic cancer that has spread beyond the breast can lead to a change in systemic therapy, and thus management, in some patients, according to a prospective study published online November 28, 2011, in the Journal of Clinical Oncology.

Roche's pertuzumab fast-tracked by FDA for breast cancer

February 9, 2012

Roche and Genentech's pertuzumab for metastatic breast cancer has been accepted for fast-track review by the US Food and Drug Administration (FDA), with an action date set for June 8.

Insight: Komen charity under microscope for funding, science

February 9, 2012

By Sharon Begley and Janet Roberts, Reuters News

The Susan G. Komen for the Cure charity defines its mission as finding a cure for breast cancer. In recent years, however, it has cut by nearly half the proportion of fundraising dollars it spends on grants to scientists working to understand the causes and develop effective new treatments for the disease.

PET Techniques Provide More Accurate Diagnosis, Prognosis in Challenging Breast Cancer Cases

February 8, 2012

By Science Daily

In two new studies featured in the February issue of The Journal of Nuclear Medicine, researchers are revealing how molecular imaging can be used to solve mysteries about difficult cases of breast cancer.

Metastatic Breast Cancer: 2012 Is the Time of Hope and Optimism

February 8, 2012

By Martin Weltz, D.O., F.A.C.P., M.B.A., M.P.H.

Despite less surgery but integrated radiation and chemotherapy, there were still over 20 percent of patients at risk for recurrence and death from metastatic disease. Remember that prior to 1972, we had no tumor markers, no estrogen or progesterone receptors to help guide our therapeutic choices.

Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Breast Cancer

February 5, 2012

By Reuters

Geron Corporation (Nasdaq: GERN) today announced that the company has completed enrollment in the randomized Phase 2 clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer (MBC). Imetelstat is an inhibitor of telomerase, which is upregulated in the vast majority of human tumors and is required for tumor cell immortality and growth.

 1 2 >